A Phase 1 First-in-Human Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Myelodysplastic Syndrome (mds)
    Myeloid Leukaemia
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) A diagnosis of: AML according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options, or High-risk or very high-risk MDS according to IPSS-R and relapsed or refractory after at least 1 course of hypomethylating therapy or induction therapy. 2) Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test (either serum or urine ß human chorionic gonadotropin [ß-hCG]).

You may not be eligible for this study if the following are true:

  • 1) Prior treatment with allogenic stem cell transplant =6 months before the first dose of study drug, has evidence of graft versus host disease, or requires immunosuppressant therapy. 2) Known central nervous system (CNS) involvement. 3) Prior solid organ transplantation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.